Essen Biotech is the lead sponsor of 17 current clinical trials in our China register. 17 are recruiting patients now. All registered phases are Phase 1/2. The drugs named most often in its trials are Aldesleukin, Fludarabine and Pembrolizumab. The most-studied condition is Autoimmune Diseases.
| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
Mesothelin and Claudin 18.2 Dual-Target CAR-T Therapy in Advanced Pancreatic Cancer
NCT07066995 · ClinicalTrials.gov ↗ · Pancreatic Cancer, Pancreatic Carcinoma, Pancreatic Cancer Non-resectable
|
Phase 1/2 | Recruiting | 2025-04 | China |
|
Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma
NCT07032129 · ClinicalTrials.gov ↗ · Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma Progression
|
Phase 1/2 | Recruiting | 2025-04 | China |
|
Sequential CAR-T Cells Targeting BCMA/CD19 in Patients With Relapsed/ Refractory Autoimmune Diseases
NCT06428188 · ClinicalTrials.gov ↗ · Autoimmune Diseases, Systemic Lupus Erythematosus, Systemic Lupus Erythematosus Acute
|
Phase 1/2 | Recruiting | 2024-05 | China |
|
Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer
NCT06530303 · ClinicalTrials.gov ↗ · Colorectal Cancer, Colon Cancer, Rectum Cancer
|
Phase 1/2 | Recruiting | 2024-09 | China |
|
TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer
NCT06532799 · ClinicalTrials.gov ↗ · Stomach Cancer, Stomach Cancer Recurrent, Stomach Cancer, Adenocarcinoma
|
Phase 1/2 | Recruiting | 2024-09 | China |
|
Investigation Into the Use of BAH243 Lentiviral Vector for Gene Therapy in Treating Sickle Cell Disease
NCT06399107 · ClinicalTrials.gov ↗ · Sickle Cell Disease, Sickle-Cell Disease With Crisis
|
Phase 1/2 | Recruiting | 2024-08 | China |
|
Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells
NCT06420076 · ClinicalTrials.gov ↗ · T Cell Lymphoma, T Cell Leukemia, T-cell Acute Lymphoblastic Leukemia
|
Phase 1/2 | Recruiting | 2024-07 | China |
|
TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas
NCT06640582 · ClinicalTrials.gov ↗ · Brain Tumor, Brain Metastases, Brain Cancer
|
Phase 1/2 | Recruiting | 2024-10 | China |
|
Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas
NCT07066982 · ClinicalTrials.gov ↗ · Sarcoma, Sarcoma, Kaposi, Sarcoma, Ewing
|
Phase 1/2 | Recruiting | 2025-05 | China |
|
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
NCT07410676 · ClinicalTrials.gov ↗ · Cancer, Sarcoma, Leukaemia
Drug: Pembrolizumab |
Phase 1/2 | Recruiting | 2026-02 | China |
|
Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)
NCT06350110 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus, Lupus Nephritis, Autoimmune Diseases
|
Phase 1/2 | Recruiting | 2024-07 | China |
|
Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).
NCT06213636 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia, Adult B-Cell, Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin Lymphoma, B-cell
|
Phase 1/2 | Recruiting | 2024-07 | China |
|
Sequential CD146 and GPC3 CAR-T Cell Therapy in Advanced Ovarian Cancer
NCT07067255 · ClinicalTrials.gov ↗ · Ovarian Cancer, Ovarian Carcinoma, Ovarian Sarcoma
|
Phase 1/2 | Recruiting | 2025-04 | China |
|
Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML
NCT06420063 · ClinicalTrials.gov ↗ · AML, Acute Myeloid Leukemia, AML, Adult Recurrent
|
Phase 1/2 | Recruiting | 2024-07 | China |
|
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
NCT07410494 · ClinicalTrials.gov ↗ · Cancer, Breast Cancer, Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1/2 | Recruiting | 2026-02 | China |
|
TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer
NCT06538012 · ClinicalTrials.gov ↗ · Lung Cancer, Lung Cancer Metastatic, Lung Cancer, Non-small Cell
|
Phase 1/2 | Recruiting | 2024-08 | China |
|
TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer
NCT06532812 · ClinicalTrials.gov ↗ · Breast Cancer, Breast Carcinoma, Breast Cancer Metastatic
|
Phase 1/2 | Recruiting | 2024-08 | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 17 | 17 |
A trial with sites in more than one country appears in each of those registers.
Sponsors with the most current trials registered for this condition.
Essen Biotech is the lead sponsor of 17 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 17 of its 17 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Its current trials name 6 drugs and biologicals as interventions. The most frequent are Aldesleukin (6), Fludarabine (6), Pembrolizumab (6), Tumor Infiltrating Lymphocytes (5) and Cyclophosphamide (4). The number in brackets is how many of its trials name each drug.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.